Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00903396 · ClinicalTrials.gov registry record · Phase 2
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00903396: Clinical Trial Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
NCT00903396 is a Phase 2 study that was terminated before completion, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00903396, a Phase 2 study, was terminated before completion, sponsored by Alliance for Clinical Trials in Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting. PURPOSE: This randomized phase II trial is studying the side effects of palonosetron hydrochloride and to see how well it works in preventing nausea and vomiting caused by radiation therapy in patients with primary abdominal cancer.
Interventions
- OTHER placebo
- DRUG palonosetron hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Why NCT00903396 stopped before completion
NCT00903396 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00903396 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00903396 about?
NCT00903396 is a clinical study titled "Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer". RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting. PURPOSE: This randomized phase II trial is studying the side effects of palon...
What is the current status of trial NCT00903396?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2009-09. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00903396?
The interventions under investigation include: placebo (OTHER), palonosetron hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00903396?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00903396's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia